Approach to the patient with secondary osteoporosis
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Secondary osteoporosis is characterized by low bone mass with microarchitectural alterations in bone leading to fragility fractures in the presence of an underlying disease or medication. Scenarios that are highly suspicious for secondary osteoporosis include fragility fractures in younger men or premenopausal women, very low bone mineral density (BMD) values, and fractures despite anti-osteoporotic therapy. An open-minded approach with a detailed history and physical examination combined with first-line laboratory tests are aimed at identifying clinical risk factors for fractures, osteoporosis-inducing drugs, and underlying endocrine, gastrointestinal, hematologic, or rheumatic diseases, which then need to be confirmed by specific and/or more invasive tests. BMD should be assessed with bone densitometry at the hip and spine. Lateral X-rays of the thoracic and lumbar spine should be performed to identify or exclude prevalent vertebral fractures which may be clinically silent. Management of secondary osteoporosis includes treatment of the underlying disease, modification of medications known to affect the skeleton, and specific anti-osteoporotic therapy. Calcium and vitamin D supplementation should be initiated with doses that result in normocalcemia and serum 25-hydroxyvitamin D concentrations of at least 30 ng/ml. Oral and i.v. bisphosphonates are effective and safe drugs for most forms of secondary osteoporosis. Severe osteoporosis may require the use of teriparatide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa074941 · Cited by 2,003
Sex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Preventing Falls in Elderly Persons
Tinetti, M. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp020719 · Cited by 1,660
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914
A meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
TSH Is a Negative Regulator of Skeletal Remodeling
Abe, E., Marians, R. C., Yu, W., Wu, X.-B., Ando, T., Li, Y., Iqbal, J., Eldeiry, L., Rajendren, G., Blair, H. C., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00771-2 · Cited by 691
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.
Staa, T. P. V., Geusens, P., Bijlsma, J. W. J., Leufkens, H. G. M., & Cooper, C. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22117 · Cited by 587
Reid, D. M., Devogelaer, J.-P., Saag, K., Roux, C., Lau, C.-S., Reginster, J.-Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60250-6 · Cited by 527
Risk for fracture in women with low serum levels of thyroid-stimulating hormone
Bauer, D. C., Ettinger, B., Nevitt, M. C., Stone, K. L., & for the Study of Osteoporotic Fractures Research Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00009 · Cited by 467
Coates, P. S., Fernstrom, J. D., Fernstrom, M. H., Schauer, P. R., & Greenspan, S. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031756 · Cited by 423
Ebeling, P. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0707217 · Cited by 332
Self-citationDiem, S. J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1240 · Cited by 326
Estrogen and the Male Skeleton
Khosla, S., Melton, L. J., & Riggs, B. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8417 · Cited by 308
Association of Low Bone Mineral Density With Selective Serotonin Reuptake Inhibitor Use by Older Men
Haney, E. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.12.1246 · Cited by 286
RANK ligand and osteoprotegerin in myeloma bone disease.
Sezer, O., Heider, U., Zavrski, I., Kühne, C. A., & Hofbauer, L. C. (2003) · Blood · doi:10.1182/blood-2002-09-2684 · Cited by 258
Self-citationThyroid Hormone Excess Rather Than Thyrotropin Deficiency Induces Osteoporosis in Hyperthyroidism
Bassett, J. H. D., O’Shea, P. J., Sriskantharajah, S., Rabier, B., Boyde, A., Howell, P. G. T., Weiss, R. E., Roux, J.-P., Malaval, L., Clement-Lacroix, P., et al. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0033 · Cited by 167
Richy, F., Ethgen, O., Bruyere, O., & Reginster, J.-Y. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1570-5 · Cited by 136
Vescovi, J. D., Jamal, S. A., & De Souza, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0518-6 · Cited by 81
Cited by
Rogers, L. C., Frykberg, R. G., Armstrong, D. G., Boulton, A. J. M., Edmonds, M., Van, G. H., Hartemann, A., Game, F., Jeffcoate, W., Jirkovska, A., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0844 · Cited by 567
Osteoporosis: the evolution of a diagnosis
Lorentzon, M., & Cummings, S. R. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12369 · Cited by 379
Utility of the trabecular bone score (TBS) in secondary osteoporosis
Ulivieri, F. M., Silva, B. C., Sardanelli, F., Hans, D., Bilezikian, J. P., & Caudarella, R. (2014) · Endocrine · doi:10.1007/s12020-014-0280-4 · Cited by 161
Impact of thyroid disease on testicular function
La Vignera, S., Vita, R., Condorelli, R. A., Mongioì, L. M., Presti, S., Benvenga, S., & Calogero, A. E. (2017) · Endocrine · doi:10.1007/s12020-017-1303-8 · Cited by 78
“Thyrotoxicosis, either due to hyperthyroidism or to levothyroxine overdose, is one of the causes of secondary osteoporosis [69].”
BackgroundMechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review
Chiodini, I., Vainicher, C. E., Morelli, V, Palmieri, S., Cairoli, E., Salcuni, A. S., Copetti, M., & Scillitani, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0289 · Cited by 73
Metadata
- Authors
- Hofbauer, L. C., Hamann, C., & Ebeling, P. R.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-06
- Volume
- 162
- Issue
- 6
- Pages
- 1009-1020
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2143737320
- Cited by
- 95
- References
- 21
- FWCI
- 7.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.